The global PARP (Poly ADP-Ribose Polymerase) Inhibitor revenue was US$ 4686.4 million in 2022 and is forecast to a readjusted size of US$ 8571.2 million by 2029 with a CAGR of 8.9% during the forecast period (2023-2029).

and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.

In India, the PARP (Poly ADP-Ribose Polymerase) Inhibitor revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2023-2029).

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%.

North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent.

In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.

This report focuses on global and India PARP (Poly ADP-Ribose Polymerase) Inhibitor market, also covers the segmentation data of other regions in regional level and county level.

India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2023, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.

India is a market full of opportunities, and the demand for PARP (Poly ADP-Ribose Polymerase) Inhibitor will continue to grow rapidly in the future.

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Scope and Market Size

PARP (Poly ADP-Ribose Polymerase) Inhibitor market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.

For India market, this report focuses on the PARP (Poly ADP-Ribose Polymerase) Inhibitor market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.

Scope of and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Report

Report Metric	Details
Report Name	and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
Forecasted market size in 2029	US$ 8571.2 million
CAGR	8.9%
Forecasted years	2023 - 2029
Segment by Type	Lynparza Zejula Rubraca Talzenna Other
Segment by Application	Ovarian Cancer Breast Cancer Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AstraZeneca, Tesaro, Merck & Co, Clovis Oncology, Pfizer, GSK, Zai Lab
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

FAQ for this report

What is the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market size in 2029?

Ans: The and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market size in 2029 will be US$ 8571.2 million.

What is the market share of major companies in and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market?

Ans: Global top three manufacturers hold a share about 90%.

What is the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market share by type?

Ans: In terms of product, Lynparza is the largest segment, with a share over 65%.

What is the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market share by region?

Ans: According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2023, powered by domestic investment.

Who are the main players in the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market report?

Ans: The main players in the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market are AstraZeneca, Tesaro, Merck & Co, Clovis Oncology, Pfizer, GSK, Zai Lab

What are the Application segmentation covered in the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market report?

Ans: The Applications covered in the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market report are Ovarian Cancer, Breast Cancer, Other

What are the Type segmentation covered in the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market report?

Ans: The Types covered in the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market report are Lynparza, Zejula, Rubraca, Talzenna, Other

1 Study Coverage

1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Introduction

1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Outlook 2018 VS 2022 VS 2029

1.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in US$ Million for the Year 2018-2029

1.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume for the Year 2018-2029

1.3 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Outlook 2018 VS 2022 VS 2029

1.3.1 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in US$ Million for the Year 2018-2029

1.3.2 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume for the Year 2018-2029

1.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size, India VS Global, 2018 VS 2022 VS 2029

1.4.1 The Market Share of India PARP (Poly ADP-Ribose Polymerase) Inhibitor in Global, 2018 VS 2022 VS 2029

1.4.2 The Growth Rate of PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size, India VS Global, 2018 VS 2022 VS 2029

1.5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Dynamics

1.5.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends

1.5.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers

1.5.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Challenges

1.5.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints

1.6 Study Objectives

1.7 Years Considered

1.8 Years Considered

2 PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type

2.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment by Type

2.1.1 Lynparza

2.1.2 Zejula

2.1.3 Rubraca

2.1.4 Talzenna

2.1.5 Other

2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type

2.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value, by Type (2018, 2022 & 2029)

2.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume, by Type (2018, 2022 & 2029)

2.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Selling Price (ASP) by Type (2018, 2022 & 2029)

2.3 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type

2.3.1 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value, by Type (2018, 2022 & 2029)

2.3.2 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume, by Type (2018, 2022 & 2029)

2.3.3 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Selling Price (ASP) by Type (2018, 2022 & 2029)

3 PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application

3.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment by Application

3.1.1 Ovarian Cancer

3.1.2 Breast Cancer

3.1.3 Other

3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application

3.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value, by Application (2018, 2022 & 2029)

3.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume, by Application (2018, 2022 & 2029)

3.3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Selling Price (ASP) by Application (2018, 2022 & 2029)

3.3 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application

3.3.1 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value, by Application (2018, 2022 & 2029)

3.3.2 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume, by Application (2018, 2022 & 2029)

3.3.3 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Selling Price (ASP) by Application (2018, 2022 & 2029)

4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Competitor Landscape by Company

4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Company

4.1.1 Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Ranked by Revenue (2022)

4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturer (2018-2023)

4.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturer (2018-2023)

4.1.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Manufacturer (2018-2023)

4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Concentration Ratio (CR)

4.2.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Concentration Ratio (CR)

4.2.2 Global Top 5 and Top 10 Largest Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor in 2022

4.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

4.3 Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Manufacturing Base Distribution and Headquarters

4.4 Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Product Offered and Application

4.5 Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Date of Enter into This Industry

4.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4.7 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Company

4.7.1 Key Players of PARP (Poly ADP-Ribose Polymerase) Inhibitor in India, Ranked by Revenue (2022)

4.7.2 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Players (2018-2023)

4.7.3 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Players (2018-2023)

5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region

5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region: 2018 VS 2022 VS 2029

5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size in Volume by Region (2018-2029)

5.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Region: 2018-2023

5.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume Forecast by Region (2024-2029)

5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size in Value by Region (2018-2029)

5.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Region: 2018-2023

5.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Region: 2024-2029

6 Americas

6.1 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size YoY Growth 2018-2029

6.2 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume, by Type (2018, 2022 & 2029)

6.3 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume, by Application (2018, 2022 & 2029)

6.4 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country (2018, 2022 & 2029)

6.4.1 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2018, 2022 & 2029)

6.4.2 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2018, 2022 & 2029)

6.4.3 United States

6.4.4 Canada

6.4.5 Mexico

6.4.6 Brazil

7 EMEA

7.1 EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size YoY Growth 2018-2029

7.2 EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume, by Type (2018, 2022 & 2029)

7.3 EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume, by Application (2018, 2022 & 2029)

7.4 EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country (2018, 2022 & 2029)

7.4.1 EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2018, 2022 & 2029)

7.4.2 EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2018, 2022 & 2029)

7.4.3 Europe

7.4.4 Middle East

7.4.5 Africa

8 China

8.1 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size YoY Growth 2018-2029

8.2 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume, by Type (2018, 2022 & 2029)

8.3 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume, by Application (2018, 2022 & 2029)

9 APAC

9.1 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size YoY Growth 2018-2029

9.2 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume, by Type (2018, 2022 & 2029)

9.3 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume, by Application (2018, 2022 & 2029)

9.4 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Region (2018, 2022 & 2029)

9.4.1 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Region (2018, 2022 & 2029)

9.4.2 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Region (2018, 2022 & 2029)

9.4.3 Japan

9.4.4 South Korea

9.4.5 China Taiwan

9.4.6 Southeast Asia

9.4.7 India

10 Company Profiles

10.1 AstraZeneca

10.1.1 AstraZeneca Company Information

10.1.2 AstraZeneca Description and Business Overview

10.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2018-2023)

10.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered

10.1.5 AstraZeneca Recent Development

10.2 Tesaro

10.2.1 Tesaro Company Information

10.2.2 Tesaro Description and Business Overview

10.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2018-2023)

10.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered

10.2.5 Tesaro Recent Development

10.3 Merck & Co

10.3.1 Merck & Co Company Information

10.3.2 Merck & Co Description and Business Overview

10.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2018-2023)

10.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered

10.3.5 Merck & Co Recent Development

10.4 Clovis Oncology

10.4.1 Clovis Oncology Company Information

10.4.2 Clovis Oncology Description and Business Overview

10.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2018-2023)

10.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered

10.4.5 Clovis Oncology Recent Development

10.5 Pfizer

10.5.1 Pfizer Company Information

10.5.2 Pfizer Description and Business Overview

10.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2018-2023)

10.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered

10.5.5 Pfizer Recent Development

10.6 GSK

10.6.1 GSK Company Information

10.6.2 GSK Description and Business Overview

10.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2018-2023)

10.6.4 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered

10.6.5 GSK Recent Development

10.7 Zai Lab

10.7.1 Zai Lab Company Information

10.7.2 Zai Lab Description and Business Overview

10.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2018-2023)

10.7.4 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered

10.7.5 Zai Lab Recent Development

11 Industry Chain and Sales Channels Analysis

11.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Chain Analysis

11.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Raw Materials

11.2.1 Key Raw Materials

11.2.2 Raw Materials Key Suppliers

11.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Mode & Process

11.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Marketing

11.4.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Channels

11.4.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors

11.5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers

12 Research Findings and Conclusion

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. PARP (Poly ADP-Ribose Polymerase) Inhibitor CAGR in Value, India VS Global, 2018 VS 2022 VS 2029

Table 2. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Trends

Table 3. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers

Table 4. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Challenges

Table 5. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints

Table 6. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (CAGR) by Type: 2018 VS 2022 VS 2029 (US$ Million)

Table 7. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (CAGR) by Type: 2018 VS 2022 VS 2029 (US$ Million)

Table 8. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (CAGR) by Application: 2018 VS 2022 VS 2029 (US$ Million)

Table 9. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (CAGR) by Application: 2018 VS 2022 VS 2029 (US$ Million)

Table 10. Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Ranked by Revenue (2022) & (US$ Million)

Table 11. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturer, (US$ Million), 2018-2023

Table 12. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Manufacturer, 2018-2023

Table 13. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturer, (K Units), 2018-2023

Table 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Manufacturer, 2018-2023

Table 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Manufacturer (2018-2023) & (USD/Unit)

Table 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PARP (Poly ADP-Ribose Polymerase) Inhibitor as of 2022)

Table 18. Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Manufacturing Base Distribution and Headquarters

Table 19. Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Product Offered and Application

Table 20. Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Date of Enter into This Industry

Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 22. Key Players of PARP (Poly ADP-Ribose Polymerase) Inhibitor in India, Ranked by Revenue (2022) & (US$ million)

Table 23. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Players, (US$ Million), (2018-2023)

Table 24. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Players, (2018-2023)

Table 25. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Players, (K Units), (2018-2023)

Table 26. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Players, (2018-2023)

Table 27. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 28. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Region (2018-2023) & (K Units)

Table 29. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume Forecast by Region (2024-2029) & (K Units)

Table 30. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Region (2018-2023) & (US$ Million)

Table 31. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Forecast by Region (2024-2029) & (US$ Million)

Table 32. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029

Table 33. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2018-2023) & (US$ Million)

Table 34. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2024-2029) & (US$ Million)

Table 35. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2018-2023) & (K Units)

Table 36. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2024-2029) & (K Units)

Table 37. EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029

Table 38. EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2018-2023) & (US$ Million)

Table 39. EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2024-2029) & (US$ Million)

Table 40. EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2018-2023) & (K Units)

Table 41. EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2024-2029) & (K Units)

Table 42. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029

Table 43. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2018-2023) & (US$ Million)

Table 44. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2024-2029) & (US$ Million)

Table 45. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2018-2023) & (K Units)

Table 46. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2024-2029) & (K Units)

Table 47. AstraZeneca Company Information

Table 48. AstraZeneca Description and Business Overview

Table 49. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 50. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product

Table 51. AstraZeneca Recent Development

Table 52. Tesaro Company Information

Table 53. Tesaro Description and Business Overview

Table 54. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 55. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product

Table 56. Tesaro Recent Development

Table 57. Merck & Co Company Information

Table 58. Merck & Co Description and Business Overview

Table 59. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 60. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product

Table 61. Merck & Co Recent Development

Table 62. Clovis Oncology Company Information

Table 63. Clovis Oncology Description and Business Overview

Table 64. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 65. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product

Table 66. Clovis Oncology Recent Development

Table 67. Pfizer Company Information

Table 68. Pfizer Description and Business Overview

Table 69. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 70. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product

Table 71. Pfizer Recent Development

Table 72. GSK Company Information

Table 73. GSK Description and Business Overview

Table 74. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 75. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product

Table 76. GSK Recent Development

Table 77. Zai Lab Company Information

Table 78. Zai Lab Description and Business Overview

Table 79. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 80. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product

Table 81. Zai Lab Recent Development

Table 82. Key Raw Materials Lists

Table 83. Raw Materials Key Suppliers Lists

Table 84. PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers List

Table 85. PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List

Table 86. Research Programs/Design for This Report

Table 87. Key Data Information from Secondary Sources

Table 88. Key Data Information from Primary Sources

List of Figures

Figure 1. PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Picture

Figure 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue, (US$ Million), 2018 VS 2022 VS 2029

Figure 3. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size 2018-2029 (US$ Million)

Figure 4. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2018-2029 (K Units)

Figure 5. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue, (US$ Million), 2018 VS 2022 VS 2029

Figure 6. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size 2018-2029 (US$ Million)

Figure 7. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2018-2029 (K Units)

Figure 8. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share in Global, in Value (US$ Million) 2018-2029

Figure 9. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share in Global, in Volume (K Units) 2018-2029

Figure 10. PARP (Poly ADP-Ribose Polymerase) Inhibitor Report Years Considered

Figure 11. Product Picture of Lynparza

Figure 12. Product Picture of Zejula

Figure 13. Product Picture of Rubraca

Figure 14. Product Picture of Talzenna

Figure 15. Product Picture of Other

Figure 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Type in 2022 & 2029

Figure 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Type (2018-2029) & (US$ Million)

Figure 18. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Type (2018-2029)

Figure 19. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2029) & (K Units)

Figure 20. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Type (2018-2029)

Figure 21. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2018-2029) & (USD/Unit)

Figure 22. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Type in 2022 & 2029

Figure 23. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Type (2018-2029) & (US$ Million)

Figure 24. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Type (2018-2029)

Figure 25. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2029) & (K Units)

Figure 26. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Type (2018-2029)

Figure 27. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2018-2029) & (USD/Unit)

Figure 28. Product Picture of Ovarian Cancer

Figure 29. Product Picture of Breast Cancer

Figure 30. Product Picture of Other

Figure 31. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Application in 2022 & 2029

Figure 32. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Application (2018-2029) & (US$ Million)

Figure 33. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Application (2018-2029)

Figure 34. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2029) & (K Units)

Figure 35. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Application (2018-2029)

Figure 36. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2018-2029) & (USD/Unit)

Figure 37. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Application in 2022 & 2029

Figure 38. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Application (2018-2029) & (US$ Million)

Figure 39. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Application (2018-2029)

Figure 40. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2029) & (K Units)

Figure 41. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Application (2018-2029)

Figure 42. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2018-2029) & (USD/Unit)

Figure 43. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume Growth Rate 2018-2029 (K Units)

Figure 44. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate 2018-2029 (US$ Million)

Figure 45. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2029) & (K Units)

Figure 46. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Type (2018-2029)

Figure 47. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2029) & (K Units)

Figure 48. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Application (2018-2029)

Figure 49. United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate (2018-2029) & (US$ Million)

Figure 50. Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate (2018-2029) & (US$ Million)

Figure 51. Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate (2018-2029) & (US$ Million)

Figure 52. Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate (2018-2029) & (US$ Million)

Figure 53. EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume Growth Rate 2018-2029 (K Units)

Figure 54. EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate 2018-2029 (US$ Million)

Figure 55. EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2029) & (K Units)

Figure 56. EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Type (2018-2029)

Figure 57. EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2029) & (K Units)

Figure 58. EMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Application (2018-2029)

Figure 59. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate (2018-2029) & (US$ Million)

Figure 60. Middle East PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate (2018-2029) & (US$ Million)

Figure 61. Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate (2018-2029) & (US$ Million)

Figure 62. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume Growth Rate 2018-2029 (K Units)

Figure 63. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate 2018-2029 (US$ Million)

Figure 64. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2029) & (K Units)

Figure 65. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Type (2018-2029)

Figure 66. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2029) & (K Units)

Figure 67. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Application (2018-2029)

Figure 68. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume Growth Rate 2018-2029 (K Units)

Figure 69. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate 2018-2029 (US$ Million)

Figure 70. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2029) & (K Units)

Figure 71. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Type (2018-2029)

Figure 72. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2029) & (K Units)

Figure 73. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Application (2018-2029)

Figure 74. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate (2018-2029) & (US$ Million)

Figure 75. South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate (2018-2029) & (US$ Million)

Figure 76. China Taiwan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate (2018-2029) & (US$ Million)

Figure 77. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate (2018-2029) & (US$ Million)

Figure 78. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value Growth Rate (2018-2029) & (US$ Million)

Figure 79. PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain

Figure 80. PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Process

Figure 81. Channels of Distribution

Figure 82. Distributors Profiles

Figure 83. Bottom-up and Top-down Approaches for This Report

Figure 84. Data Triangulation

Figure 85. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4350

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$6525

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$8700

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-9U20281

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global AI Contouring Software for Radiotherapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32T20006

Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Cell Senescence β-Galactosidase Staining Kit Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-0Q20500

Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Kinase Inhibitors For Cancer Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-18V16958

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Report & Forecast 2023-2029

Published Date: November 2023

Report Code: QYRE-Auto-19N16014

Global and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Report & Forecast 2023-2029

FEATURED COMPANIES

and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size

and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market

Scope of and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Report

FAQ for this report

What is the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market size in 2029?

What is the market share of major companies in and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market?

What is the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market share by type?

What is the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market share by region?

Who are the main players in the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market report?

What are the Application segmentation covered in the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market report?

What are the Type segmentation covered in the and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market report?

FEATURED COMPANIES

RELATED REPORTS